Neurocrine Biosciences Inc. (NBIX)
NASDAQ
Closed
Aug 24, 2026
Day's Range
151.9052 wk Range
122.14Overview - NBIX - Neurocrine Biosciences Inc.
Key Statistics
Valuation
Enterprise Value
15.58B
P/E (Trailing)
‪22.33‬
P/E (Forward)
‪12.76‬
PEG Ratio
‪0.71‬
Price / Sales (TTM)
‪4.59‬
Price / Book
‪4.19‬
EV / EBITDA
‪17.05‬
Profitability
Gross Margin
‪97.58%‬
Profit Margin
‪20.91%‬
Operating Margin
‪22.19%‬
Return on Assets
‪11.70%‬
Return on Equity
‪22.08%‬
Ownership
Shares Outstanding
101.60M
Float
100.38M
Short % of Shares Outstanding
‪5.61%‬
Held by Insiders
‪1.06%‬
Held by Institutions
‪102.80%‬
Price stats
Beta
‪0.39‬
50-Day Avg
‪166.94‬
200-Day Avg
‪147.16‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
27 analysts
Average price target
‪$ 211.57‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - NBIX - Neurocrine Biosciences Inc.
Peers - NBIX - Neurocrine Biosciences Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- NBIXNASDAQNeurocrine Biosciences Inc.15.55BMarket Cap+12.43%52-week change22.34P/E (Trailing)‪20.91%‬Profit Margin
- ALALKSNASDAQAlkermes plc8.10BMarket Cap+40.00%52-week change127.18P/E (Trailing)‪3.96%‬Profit Margin
- LNTHNASDAQLantheus Holdings, Inc.6.52BMarket Cap+44.07%52-week change23.92P/E (Trailing)‪17.69%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals Inc.6.19BMarket Cap+47.82%52-week change37.31P/E (Trailing)‪5.04%‬Profit Margin
- KNKNSANASDAQKiniksa Pharmaceuticals International, plc6.16BMarket Cap+58.19%52-week change79.83P/E (Trailing)‪9.59%‬Profit Margin
- ALMNASDAQAlmonty Industries Inc.5.33BMarket Cap+76.82%52-week change84.14P/E (Trailing)‪125.23%‬Profit Margin
- INDVNASDAQIndivior Pharmaceuticals, Inc.4.35BMarket Cap+34.88%52-week change13.22P/E (Trailing)‪26.74%‬Profit Margin
Profile Summary - NBIX - Neurocrine Biosciences Inc.
About
Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company headquartered in San Diego, California. The company specializes in discovering, developing, and commercializing medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its marketed portfolio addresses a range of…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
